Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
Open Access
- 24 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9), e44260
- https://doi.org/10.1371/journal.pone.0044260
Abstract
Changes in brain amyloid burden have been shown to relate to Alzheimer's disease pathology, and are believed to precede the development of cognitive decline. There is thus a need for inexpensive and non-invasive screening methods that are able to accurately estimate brain amyloid burden as a marker of Alzheimer's disease. One potential method would involve using demographic information and measurements on plasma samples to establish biomarkers of brain amyloid burden; in this study data from the Alzheimer's Disease Neuroimaging Initiative was used to explore this possibility. Sixteen of the analytes on the Rules Based Medicine Human Discovery Multi-Analyte Profile 1.0 panel were found to associate with [11C]-PiB PET measurements. Some of these markers of brain amyloid burden were also found to associate with other AD related phenotypes. Thirteen of these markers of brain amyloid burden – c-peptide, fibrinogen, alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cortisol, AXL receptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolipoprotein E and immunoglobulin E – were used along with co-variates in multiple linear regression, and were shown by cross-validation to explain >30% of the variance of brain amyloid burden. When a threshold was used to classify subjects as PiB positive, the regression model was found to predict actual PiB positive individuals with a sensitivity of 0.918 and a specificity of 0.545. The number of APOE ϵ 4 alleles and plasma apolipoprotein E level were found to contribute most to this model, and the relationship between these variables and brain amyloid burden was explored.This publication has 46 references indexed in Scilit:
- Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer DiseaseArchives of Neurology, 2012
- Apolipoprotein E controls cerebrovascular integrity via cyclophilin ANature, 2012
- Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome DatasetPLOS ONE, 2012
- Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairmentNeuroImage, 2012
- Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic TreatmentsJournal of Alzheimer's Disease, 2011
- Plasma apolipoprotein E and Alzheimer disease riskNeurology, 2011
- Interleukin-3 prevents neuronal death induced by amyloid peptideBMC Neuroscience, 2007
- Proteome-based plasma biomarkers for Alzheimer's diseaseBrain, 2006
- Mining biomarkers in human sera using proteomic toolsProteomics, 2004
- Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Studycclm, 2000